Most conversations about heart failure treatment center on ejection fraction, the percentage of blood the heart pumps out with each contraction. It's a very important number, and an incomplete one on its own, as one of the largest stem cell trials ever run in heart failure demonstrates directly.

The Trial

DREAM-HF was a Phase 3 randomized controlled trial led by Perin and colleagues at the Texas Heart Institute, enrolling 537 patients with heart failure. Overall, mesenchymal stem cell (MSC) therapy reduced major adverse cardiac events (MACE) by 28% compared to placebo. The more interesting number sits inside a subgroup: in patients with elevated inflammation (CRP of 2 mg/L or higher), MACE dropped by 75%, and cardiac death or nonfatal heart attack or stroke dropped by 58%.

JACC, 2023 — Perin et al., DREAM-HF Phase 3 RCT (n=537) — MSC therapy reduced MACE 28% overall, 75%/58% in patients with elevated inflammation.

A follow-up study extending the same patient cohort to 30 months found the effect held up: an 88% reduction in MACE in the high-inflammation group.

European Journal of Heart Failure, 2025 — Perin et al., extended 30-month DREAM-HF follow-up — 88% MACE reduction in patients with elevated inflammation.

Inflammation and The Heart

Ejection fraction tells you how the heart is performing mechanically; the underlying cause is a separate question entirely. A significant share of heart failure progression comes from chronic low-grade inflammation: damaged tissue signaling for repair that never fully arrives, and immune cells stuck in a self-sustaining cycle of tissue stress that never resolves. Two patients with identical ejection fractions can carry very different amounts of that inflammatory burden, and DREAM-HF suggests they respond very differently to MSC therapy as a result.

This lines up with how MSCs work mechanistically. Their primary effect is paracrine: they release signaling molecules, cytokines like IL-10 and TGF-beta, that calm the inflammatory environment, shift immune cells away from a destructive state, and support the heart's own repair processes. In a heart where inflammation is the dominant driver of decline, that mechanism has more to work with.

The Dosing Question Underneath This

This finding connects to a broader pattern across MSC research: response depends heavily on getting the right cells to the right patient in the right amount. A 2020 analysis of 914 MSC trials from ClinicalTrials.gov found a narrow effective dose range for IV delivery, generally 100 to 150 million cells, with doses below or above that range consistently underperforming across multiple conditions.

Stem Cells Translational Medicine, 2020 — Kabat et al.; analysis of 914 MSC trials — narrow minimum-effective-dose range of 100–150M cells for IV delivery across conditions.

Put the inflammation finding and the dosing finding together, and a clear picture emerges: MSC therapy for organ function depends on identifying which patients have the biological profile the therapy is best suited to address, and dosing appropriately once you have.

Why This Shapes How We Evaluate Candidates

This is a large part of why a full medical history and lab review comes before any specific protocol recommendation at SOMA. Two patients with heart failure can carry very different disease drivers, even when their diagnosis reads identically on paper. Identifying inflammatory burden, alongside dosing appropriately for the patient's condition and cell profile, is what separates a general therapy from one built around the evidence for who responds.

What DREAM-HF shows is a meaningfully reduced risk of the events that matter most for extending everyday patients lives with Mesenchymal stem cells that are produced under the most optimal conditions.